Neovasc Inc. announced the US Food and Drug Administration (FDA) has granted approval for participating physicians to treat patients with its 40mm Tiara valve in the company's TIARA-I Early Feasibility Trial. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted at centers in the US, Europe and Canada to assess the safety and performance of Neovasc's Tiara Mitral Valve System and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).
1st Jan change | Capi. | |
---|---|---|
+4.57% | 212B | |
+8.61% | 187B | |
+26.34% | 155B | |
+33.90% | 115B | |
+2.17% | 65.5B | |
+14.50% | 52.87B | |
-3.30% | 45.25B | |
-3.98% | 39.7B | |
+6.66% | 37.72B |